Management of anticoagulant-related intracranial hemorrhage: An evidence-based review

Bappaditya Ray
University of Oklahoma Health Sciences Center

Salah G. Keyrouz
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Ray, Bappaditya and Keyrouz, Salah G., "Management of anticoagulant-related intracranial hemorrhage: An evidence-based review." Critical Care. 18, 3. 223. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2932

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Management of anticoagulant-related intracranial hemorrhage: an evidence-based review

Bappaditya Ray1* and Salah G Keyrouz2

Abstract
The increased use of anticoagulants for the prevention and treatment of thromboembolic diseases has led to a rising incidence of anticoagulant-related intracranial hemorrhage (AICH) in the aging western population. High mortality accompanies this form of hemorrhagic stroke, and significant and debilitating long-term consequences plague survivors. Although management guidelines for such hemorrhages are available for the older generation anticoagulants, they are still lacking for newer agents, which are becoming popular among physicians. Supportive care, including blood pressure control, and reversal of anticoagulation remain the cornerstone of acute management of AICH. Prothrombin complex concentrates are gaining popularity over fresh frozen plasma, and reversal agents for newer anticoagulation agents are being developed. Surgical interventions are options fraught with complications, and are decided on a case-by-case basis. Our current state of understanding of this condition and its management is insufficient. This deficit calls for more population-based studies and therapeutic trials to better evaluate risk factors for, and to prevent and treat AICH.

Introduction
Use of anticoagulation therapy among the older western population for varied thromboembolic diseases potentially places them at risk of developing anticoagulant-related intracranial hemorrhage (AICH). The indications for use of anticoagulants are published in a guideline statement by the American College of Chest Physicians [1], to which readers are referred. AICH can be spontaneous or traumatic, and can occur in different intracranial compartments (for example, subdural hemorrhage, epidural hemorrhage, subarachnoid hemorrhage, or intracerebral hemorrhage (ICH)). Most clinical data on AICH are related to ICH, while extraparenchymal hemorrhages are reported but data on these are sparse.

In the absence of clinical evidence, definitive guidelines, and proven therapies, clinicians are left scrambling for rapid correction of the coagulopathy and maintaining homeostasis to prevent secondary brain injury. The basic pharmacological properties of commonly used anticoagulants, their mechanism of action, and their indications are presented in Table 1 and Figure 1. Interested readers are referred to recently published articles for in-depth reviews of these agents [2,3]. The present review will primarily focus on the importance and impact of AICH, and, where available, the evidence-based management of this mostly iatrogenic disease.

Epidemiology
The use of anticoagulants has increased exponentially over the last two decades along with the incidence of atrial fibrillation in aging western populations [4-6]; 5.6 million patients in the USA will be on anticoagulation for atrial fibrillation by 2050 [7]. With this increased use, the incidence of AICH has risen; the Greater Cincinnati area has seen a threefold increase in incidence during a 10-year period [8]. It is unclear whether a similar trend is still persistent with the introduction of newer generation oral anticoagulants (see below). Warfarin – the most commonly used, and therefore most extensively studied, long-term oral anticoagulant – is responsible for 9 to 14% of ICH [9-11] and carries 0.3 to 3.7% annual risk of warfarin-related intracerebral hemorrhage (WRICH) when the International Normalized Ratio (INR) is between 2 and 4.5 [12]. The risk of ICH in patients on long-term anticoagulation is 8 to 11 times higher than that of age-matched cohorts not taking anticoagulants [13,14]. Advanced age (≥70 years) [15,16], hypertension [9,14,15,17] and concurrent use of single or dual antiplatelets [18] are risk factors for WRICH. Other established risk factors include the early period after warfarin...
| Drug   | Target                  | Antithrombin dependent | Route | Half-life (hours) | Protein binding | Renal excretion          | Monitoring | Antidote       | Common indications                                                                 |
|--------|-------------------------|------------------------|-------|------------------|-----------------|--------------------------|------------|----------------|------------------------------------------------------------------------------------|
| Warfarin | Factors II, VII, IX, X; proteins C, S | No                      | p.o.  | 30 to 40 | 99%              | 92%                     | INR        | Vitamin K    | Thromboembolic prophylaxis in AF. Treatment of VTE. Thrombosis prophylaxis in prosthetic valve. |
| UFH    | Factors II, Xa (Vila, IXa, XIa, XIIa) | Yes                     | i.v., s.c. | 0.5 to 2.5 (dose dependent) | Variable         | Mostly after hepatic metabolism | aPTT       | Protamine sulfate | ACS. Thromboprophylaxis. Thromboembolic diseases (including ischemic stroke, CVST) in acute phase. |
| LMWH   | Factors IIa, Xa         | Yes                     | s.c., i.v. | Variable according to the product | Variable         | 40% (10% unchanged) | Anti-factor Xa | Protamine sulfate (60%) | ACS. Thromboprophylaxis. Thromboembolic diseases. |
| Fondaparinux | Factor Xa | Yes                      | s.c. | 17 to 21 | 94%              | ~100% (77% unchanged) | Anti-factor Xa | None (see text) | VTE. Thromboprophylaxis. Selected cases of HIT. |
| Argatroban | Factor IIa | No                      | i.v. | 0.75 (prolonged in hepatic dysfunction) | 54%              | 22% (16% unchanged) | aPTT, ACT | None | HIT. Thromboprophylaxis in patients suspected of HIT. ACS. |
| Bivalirudin | Factor IIa | No                      | i.v. | 0.5 (prolonged in renal impairment) Only to factor IIa | 20% unchanged | ECT (PT, aPTT, ACT has nonlinear prolongation) | None | None | HIT. ACs after thrombolysis. Thromboembolic prophylaxis during interventional procedures. |
| Dabigatran | Factor IIa | No                      | p.o. | 12 to 14 | 35%              | 80%                     | Modified TT/ECT/anti-factor IIa (also see Table 3) | PCC/FEIBA™/rFVIIa (see text) | Thromboembolic prophylaxis in AF. Treatment and thromboprophylaxis of VTE. |
| Apixaban | Factor Xa | No                      | p.o. | 8 to 14    | 87%              | ~25%               | Anti-factor Xa (also see Table 3) | PCC/FEIBA™/rFVIIa (see text) | Thromboembolic prophylaxis in AF. Treatment and thromboprophylaxis of VTE. |
| Rivaroxaban | Factor Xa | No                      | p.o. | 7 to 11    | 93%              | 66% (33% unchanged) | Anti-factor Xa (also see Table 3) | PCC/FEIBA™/rFVIIa (see text) | Thromboembolic prophylaxis in AF. Treatment and thromboprophylaxis of VTE. |

ACS, acute coronary syndrome; ACT, activated clotting time; AF, atrial fibrillation; aPTT, activated partial thromboplastin time; CVST, cerebral venous sinus thrombosis; ECT, ecarin clotting time; HIT, heparin-induced thrombocytopenia; INR, International Normalized Ratio; i.v., intravenous; LMWH, low molecular weight heparin; PCC, prothrombin complex concentrate; p.o., per oral; PT, prothrombin time; rFVIIa, activated recombinant factor VIIa; s.c., subcutaneous; TT, thrombin time; UFH, unfractionated heparin; VTE, venous thromboembolism. FEIBA™ from Baxter (Deerfield, IL, USA).
initiation [9,13,19], supratherapeutic levels of anticoagulation [9,14,17,20-23] and associated leukoaraiosis [21,23]. Similarly, unfractionated heparin (UFH) – a parenteral anticoagulant for various indications – also carries a risk of AICH. The incidence of symptomatic ICH used with UFH or heparinoids is 1 to 2.7% in patients with acute ischemic stroke [24,25]. A direct thrombin inhibitor, argatroban, another commonly used short-term parenteral anticoagulant, is associated with a 4.3% incidence of AICH [26].

In contrast, there are promising yet limited clinical data on AICH associated with the use of newer oral anticoagulants. The results of recent clinical trials using these drugs are presented in Table 2. The rates of ICH were 0.74%, 0.30%, and 0.23% per year among those assigned to warfarin, dabigatran 150 mg, and dabigatran 110 mg respectively in the RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) trial, which assessed the efficacy of this oral direct thrombin inhibitor in atrial fibrillation [27]. In contrast, in the RE-COVER (Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism) trial, which compared dabigatran and warfarin in acute venous thromboembolism, there were no incidences of ICH during 6 months of therapy [28]. The yearly incidence of AICH ranged between 0.33 and 0.35% for apixaban, an oral factor Xa inhibitor, in two different trials – the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events) trial and the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes) trial [29,30]. The incidence of AICH linked to rivaroxaban, another oral factor Xa inhibitor, in the ROCKET-AF (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study was 0.49%; that of warfarin was 0.74% (P < 0.05) [31]. However, in the EINSTEIN-PE (Oral Rivaroxaban Alone for the Treatment of Symptomatic Pulmonary Embolism) trial – a study that compared the efficacy of rivaroxaban with that of enoxaparin followed by warfarin in patients with pulmonary embolism – the incidence of AICH was lower for rivaroxaban (0.1% vs. 0.5%; P = 0.003) [32]. For cerebrovascular indication, national registry data showed similar peri-procedural incidence of ICH with bivalirudin and UFH after carotid stenting (0.1% vs. 0.2%; odds ratio = 0.62, 95% confidence interval = 0.20 to 1.91; P = 0.41) [33].

Outcomes after AICH have been mostly studied in patients on warfarin. Patients with WRICH fare worse than those with ICH without coagulopathy, with case fatality rates ranging between 44 and 68% [34-36]. In the Greater Cincinnati study, patients on warfarin with INR > 3.0 had larger hematomas than other patients [37]. After presentation, hematoma enlargement is more common and could still occur beyond the first 24 hours in anticoagulated patients [37-39]. What is more worrisome is that hematoma could still expand despite rapid correction of coagulopathy [40]. Little is known about the outcome of patients with AICH related to the newer anticoagulants; however, with an expected rise in use as they get wider acceptance [41], physicians on the forefront are likely to encounter more patients with such hemorrhages.

**Management**

There are several uncertainties in the management of AICH. These uncertainties include the lack of evidence and limited guidelines for using biological products and pharmacologic agents, and accurate, quick, and meaningful laboratory testing to evaluate the hemostatic system. Moreover, individual variation in response to therapy and the difficulty in assessing ongoing bleeding make it even more challenging to manage this clinical problem [42]. One should also note that the mere correction of a laboratory parameter (that is, an *ex vivo* test) might not correlate with
Table 2  Intracranial hemorrhage rates reported in phase 3 clinical trials of dabigatran, rivaroxaban and apixaban related to stroke prevention and treatment of acute venous thromboembolism

| Clinical trial | Indication | Inclusion criteria | Drug | Primary outcome | Intracranial bleeding |
|----------------|------------|--------------------|------|----------------|-----------------------|
| RE-LY          | Stroke prevention in nonvalvular atrial fibrillation | AF patients with moderate to high risk of stroke or systemic embolism with at least one of the following: age >75 years; h/o TIA or stroke; LVEF <40%; NYHA class II or higher; age 65 to 74 years with either DM, CAD, hypertension | Dabigatran 110 mg or 150 mg BID; warfarin with target INR 2 to 3 | Prevention of stroke/systemic embolism: dabigatran 110 mg, 1.54%/year; dabigatran 150 mg, 1.11%/year; warfarin, 1.71%/year | AICH: dabigatran 110 mg, 0.23%/year; dabigatran 150 mg, 0.30%/year (P < 0.05); warfarin, 0.74%/year |
| ROCKET-AF      | Stroke prevention in nonvalvular atrial fibrillation | AF with history of stroke or TIA. AF with two or more of the following: symptomatic heart failure or LVEF <35%; age >75 years; DM | Rivaroxaban 20 mg daily; warfarin with target INR 2 to 3 | Prevention of stroke/systemic embolism: rivaroxaban, 2.12%/year; warfarin, 2.42%/year | AICH (all): rivaroxaban, 0.49%/year (P < 0.05); warfarin, 0.74%/year. ICH: rivaroxaban, 0.33%/year; warfarin, 0.49%/year. SDH: rivaroxaban, 0.13%/year; warfarin, 0.27%/year |
| ARISTOTLE      | Stroke prevention in nonvalvular atrial fibrillation | AF with one or more of following: TIA or systemic embolism; symptomatic CHF or LVEF ≤40%; DM or hypertension on pharmacological treatment | Apixaban 5 mg BID; warfarin with target INR 2 to 3 | Prevention of stroke/systemic embolism: apixaban, 1.27%/year; warfarin, 1.60%/year | AICH: apixaban, 0.33%/year; warfarin, 0.80%/year |
| RE-COVER       | VTE recurrence prevention | Acute symptomatic DVT of legs or PE | Dabigatran 150 mg BID; warfarin with target INR 2 to 3 | Thromboembolism or related deaths: dabigatran, 2.4%; warfarin, 2.1% | AICH: dabigatran, 0; warfarin, 0.24% |
| RECOVER II     | VTE recurrence prevention | Acute symptomatic DVT of legs or PE | Dabigatran 150 mg BID; heparin/enoxaparin followed by warfarin with target INR 2 to 3 | Recurrent VTE: dabigatran, 2.3%; warfarin, 2.2% | Not reported |
| EINSTEIN-DVT   | Prevention of VTE recurrence | Acute symptomatic DVT | Rivaroxaban 15 mg BID x 3 weeks followed by 20 mg daily. Standard therapy: enoxaparin 1 mg/kg BID; bridging warfarin or acenocoumarol therapy with target INR 2 to 3 | Recurrent VTE: rivaroxaban, 2.1%; enoxaparin-VKA, 3.0% | AICH data not reported separately. Bleeding in critical location: rivaroxaban, 0.2%; enoxaparin-VKA, 0.2% |
| EINSTEIN-PE    | VTE prevention | Acute PE | Rivaroxaban 15 mg BID x 3 weeks followed by 20 mg daily. Standard therapy: enoxaparin 1 mg/kg BID; bridging warfarin or acenocoumarol therapy with target INR 2 to 3 | Recurrent VTE: rivaroxaban, 2.1%; standard therapy, 1.8% | AICH: rivaroxaban, 0.12%; standard therapy, 0.50% |

AF, atrial fibrillation; AICH, anticoagulant-related intracranial hemorrhage; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events; BID, twice daily; CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; DVT, deep venous thrombosis; EINSTEIN-PE, Oral Rivaroxaban Alone for the Treatment of Symptomatic Pulmonary Embolism; h/o, history of; INR, International Normalized Ratio; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PE, pulmonary embolism; RE-COVER, Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism; RE-LY, Randomized Evaluation of Long Term Anticoagulant Therapy; ROCKET-AF, Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SDH, subdural hematoma; TIA, transient ischemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism.
reversal of coagulopathy in vivo as often demonstrated by the expansion of AICH even after such correction [40]. Given the emergent nature of AICH and their unpredictability, randomized clinical trials or even large cohort studies in this population are unlikely and recommendations regarding treatment strategies will continue to be based on case series and anecdotal experience [43].

Principles and interpretation of monitoring anticoagulant therapy

Evaluating and monitoring blood coagulation parameters is imperative after AICH. This is particularly true when obtaining history is difficult, thus precluding knowledge of the culprit anticoagulant, information that is crucial to guide therapy. Although coagulation tests are mere surrogate markers for hemostasis, the effect of different anticoagulants on the coagulation system is important knowledge for the treating clinician to have. Some of these tests are quantitative, and others provide only qualitative information. Moreover, it is important to understand that testing techniques and their sensitivities vary widely especially with newer anticoagulants [44].

Routine and commonly used ex vivo coagulation tests are the prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT); the thrombin time, ecarin clotting time, activated clotting time and endogenous thrombin potential are also available, albeit less widely. The plasma factors responsible for different coagulation assays and their alteration with oral anticoagulants are presented in Table 3 [45,46]. In patients with ongoing hemorrhage, the PT is preferred over the aPTT for the estimation of coagulation factor levels, because the results are quickly available, it offers a good correlation with average factor concentrations and response to plasma replacement, and there is no interference with nonspecific lupus anticoagulant inhibitors, elevated factor VIII, and heparin contamination [47]. The modified thrombin time (also commercially known as the HEMOCLOT thrombin time assay; Aniara, West Chester, OH, USA) and ecarin clotting time are the best tests for measuring the anticoagulant effect of dabigatran [48]. A normal thrombin time would exclude clinically significant dabigatran in systemic circulation. Although anti-factor IIa level testing is available at present, not enough information on its characteristics is known – such as linearity for and responsiveness in patients on dabigatran. To the contrary, the anti-factor Xa level has good correlation with rivaroxaban/apixaban activity. The recommended test to measure the anticoagulant effect of rivaroxaban is the PT (using reagent Neoplastin Plus®; Diagnostica Stago, Asnières-sur-Seine, France) and anti-factor Xa assay. Dabigatran and rivaroxaban drug levels can be used as surrogate markers to assess the need for anticoagulation reversal, but they are also not widely available [48-50].

Both warfarin and heparin have good linear correlation with the PT/INR and the aPTT respectively, but the utility of the traditional coagulation profile testing is questioned with the advent of newer anticoagulants (see Table 3). Viscoelastic assays that measure whole blood coagulation and provide a dynamic coagulation profile, such as thromboelastography and rotational thromboelastometry, are being increasingly used to provide rapid assessment of hemostasis [51]. These assays measure the increasing viscoelasticity of blood as it clots, which is proportional to clotting factors and platelet count/function [52]. Their advantages are a rapid turnaround time, and the detection of fibrinolysis. Clinical situations where viscoelastic assays

Table 3 Interpretation of coagulation tests with US Food and Drug Administration approved oral anticoagulants

| Coagulation test | Factors evaluated | Interpretation with dabigatran | Interpretation with apixaban | Interpretation with rivaroxaban | Interpretation with warfarin |
|------------------|-------------------|-------------------------------|-----------------------------|-------------------------------|-------------------------------|
| PT               | Factors II, V, VII, X, fibrinogen | Linear and dose dependent prolongation; at therapeutic range prolongs 1.2 times the basal value | Prolonged but not well studied or standardized | Linear and dose dependent prolongation; at therapeutic range prolongs 1.5 times the basal value | Prolonged |
| aPTT             | Factors II, V, VIII, IX, X, fibrinogen | Qualitative; prolongation dose dependent but not linear; at therapeutic range prolongs 2.5 times the basal value | Prolonged but not well studied or standardized | Linear and dose dependent prolongation; at therapeutic range prolongs 1.5 times the basal value | May be prolonged |
| TT               | Fibrinogen | Linear and dose dependent prolongation; but prolongation may be excessive and requires dilution of the plasma samples | Data not available | Not affected | Not affected |
| ECT              | Factor II | Linear and dose dependent prolongation; at therapeutic range prolongs three times the basal value | NA | NA | NA |
| ETP              | Factor II | Decreased – concentration dependent | Decreased – concentration dependent | Decreased – concentration dependent | NA |

aPTT, activated partial thromboplastin time; ECT, ecarin clotting time; ETP, endogenous thrombin potential (thrombin generation assay); NA, not applicable; PT, prothrombin time; TT, thrombin time.
have been used to evaluate hemostasis include trauma resuscitation [53], during cardiopulmonary bypass [54] and AICH [55]. One study reported dose-dependent shortening of the clot-lysis time in the presence of dabigatran [56]. These laboratory tests might hold promise in the near future, although further studies and experience are needed.

**Reversal of anticoagulation**

Most authorities consider rapid and adequate reversal of anticoagulation as the cornerstone of therapy in AICH, despite the lack of evidence showing that correction of coagulopathy reduces the incidence of hematoma growth or improves outcome [40]. In certain situations, however – such as the presence of a mechanical valve, INR < 3, small hemorrhage, or no surgical intervention needed – some authorities advocate holding warfarin without actively reversing coagulopathy [57]. Antidotes specific to each anticoagulant are presented in Table 1. Although warfarin remains the most commonly used oral anticoagulant, newer agents are gaining popularity. The exact mechanism of the occurrence of WRICH remains speculative, but potentially involves a local vasculopathy and/or systemic atheroembolism [57]. Precautionary measures to mitigate WRICH could therefore be relatively inexpensive, and the onus is on rapid coagulopathy reversal [59]. The same probably holds true for AICH related to newer anticoagulants. Hence, the first step in any AICH is to discontinue the offending drug, administer an antidote (if available) and monitor adequate reversal of anticoagulation. In the case of warfarin, theoretically adequate hemostasis is restored at an INR of ~1.5 since adequate quantities of the factors needed for ex vivo coagulation are restored. However, an optimal INR value is unknown. Unfortunately, parameters for adequate reversal with newer anticoagulants are yet to be defined. Despite concern among physicians for reversing anticoagulation in a prothrombotic state, available evidence with WRICH, albeit meager, supports correcting the coagulopathy in such cases [59-61].

**Vitamin K**

Vitamin K 5 to 10 mg intravenously by slow infusion over 30 minutes is administered to all patients with WRICH. Anaphylactic reactions are uncommon, and are mitigated by a slow infusion rate. The subcutaneous route for the administration of vitamin K is less effective because of erratic absorption, and the enteral route provides slow absorption although it has an equivalent bioavailability to the intravenous route [62]. The action of vitamin K is slow; it takes 6 to 24 hours to replenish adequate concentrations of factors II, VII, IX and X and to restore hemostasis [63,64]. This warrants the administration of fresh frozen plasma (FFP), prothrombin complex concentrate (PCC) and/or recombinant activated factor VII (rFVIIa) to rapidly replenish deficient factors. One should note that these agents have a short half-life, and are practically used as bridging therapy until vitamin K becomes effective.

**Fresh frozen plasma**

FFP contains all coagulation factors and is the most commonly used reversal agent in the USA due to its wide availability and physicians’ familiarity with it. The recommended dose is anywhere between 10 and 40 ml/kg [12,64]; in clinical practice, however, FFP is commonly under-dosed for fear of volume overload. Allergic reactions, possible transmission of infectious diseases, transfusion-related acute lung injury [65] and, most importantly, a time lag to administration (due to thawing, cross-matching, prolonged infusion time) have sparked interest in a more optimal way to replete factors. Lee and colleagues reviewed records of 45 patients with WRICH treated with FFP [66]. The median time from door to INR normalization was 30 hours (14 to 49.5 hours), with four patients’ hematomas enlarging after normalization. The disadvantages of using FFP can be mitigated by procurement of male donors to minimize transfusion-related acute lung injury or of universal (AB group) donors, and by using liquid plasma – plasma that is never frozen, thus bypassing the thawing process [67].

**Prothrombin complex concentrate**

Commonly available PCCs contain varying combinations and concentrations of factor II, VII, IX and X, protein C, protein S and protein Z. Some contain heparin and antithrombin to reduce thrombogenic potency. PCCs are prepared from virally inactivated plasma, pooled from several donors [43]. The concentrates come in two forms: one containing the inactivated form of coagulation factors, and another containing the activated form, such as FEIBA™ (Baxter, Deerfield, IL, USA).

Inactivated four-factor PCCs are available in Europe and Australia. Until recently, only three-factor PCCs (factor II, IX and X) have been used in the USA. Kcentra™ (CSL Behring, King of Prussia, PA, USA) is the first inactivated four-factor PCC approved by the US Food and Drug Administration to correct warfarin-related coagulopathy. The lack of comparative data on the efficacy of the three-factor versus four-factor PCCs makes it difficult to recommend one over the other [43], but the theoretical disadvantage of three-factor PCC led clinicians to supplement it with either FFP or rFVIIa. In clinical practice, PCCs are dosed based on factor IX content in a given preparation. The half-lives of the component factors II, VII, IX, and X are 60 hours, 4 to 6 hours, 17 to 24 hours, and 31 hours, respectively [68]. The dose varies between 25 and 100 units/kg, depending on the degree of INR derangement, and is infused, following reconstitution, at a rate of 100 units/minute [69,70]. The efficacy and safety of four-factor
PCC as compared with FFP were demonstrated in a recently reported randomized trial that showed faster repletion of coagulation factors and similar adverse effect profile in either cohort [71].

FEIBA™ is an anti-inhibitor coagulant complex that is US Food and Drug Administration approved for use in hemophilics. The complex has been used off-label in WRICH [72]. The recommended dose of FEIBA™ is 500 to 1,000 units, and the infusion rate should not exceed 2 units/kg/minute. The INR and fibrinogen should be checked 30 minutes after the end of infusion, and the dose may need to be repeated. Cryoprecipitate may be needed if the fibrinogen concentration is less than 100 mg/dl. Overcorrection of INR is possible and could lead to thrombotic complications such as superficial thrombophebitis, arterial or venous thrombosis and disseminated intravascular coagulation. Such complications are mostly dose related and their incidence in warfarin reversal is low [59]. Moreover, these adversities could be partly due to the underlying primary disease process [71,73,74]. An important factor that limits the availability of PCCs is their prohibitive cost [69], although a recent analysis suggested that they might be more cost-effective than FFP for warfarin reversal after life-threatening hemorrhages such as ICH [75].

Studies have demonstrated rapid and effective reversal of the coagulopathy but PCC efficacy is still speculative in the setting of WRICH [76,77]. In a study of 55 patients with WRICH, 31 of whom were treated with PCC, there was faster INR correction and reduction of hematoma growth at 24 hours [76]. Conversely, in another study of 141 patients there was ICH expansion in 45.5% of patients, despite correction of coagulopathy; in-hospital mortality was 42.3% [40]. A retrospective study comparing FFP and PCC for the reversal of warfarin's effect in WRICH did not demonstrate a significant difference in 30-day mortality [78]. An ongoing randomized control study is set to shed more light on this question [79]. In clinical practice, hemorrhages associated with the use of newer anticoagulants (dabigatran, rivaroxaban, and apixaban) are also managed with infusion of PCCs (25 to 50 units/kg) [80]. Both four-factor PCC and FEIBA™ (80 units/kg) have been demonstrated to increase thrombin generation in healthy volunteers on dabigatran and rivaroxaban [45,81].

Recombinant activated factor VII

rFVIIa is a US Food and Drug Administration-approved treatment for congenital factor VII deficiency and hemophilics with inhibitors to factor VIII. This treatment has been used to correct coagulopathy associated with warfarin [82]. rFVIIa has a dual mechanism of action that involves initiating coagulation via the tissue factor and factor VIIa pathway and direct platelet activation resulting in a thrombin burst [83]. Given its short half-life (3 to 4 hours), INR reversal after rFVIIa dosing is transient, and vitamin K and PCC/FFP should be used concomitantly. Lower doses of 10 to 40 μg/kg are associated with a lower incidence of thrombotic complications [84,85]. Although INR is corrected rapidly using rFVIIa, it may simply reflect the ex vivo effect of factor VIIa on the PT assay and may not always correlate with clinical hemostasis [86,87]. This is also reflected in the ex vivo assays where rFVIIa has been shown to reverse INR in patients on warfarin with minimal effect on aPTT and bleeding time [88]. rFVIIa is effective in reversal of the anticoagulant effect of fondaparinux in healthy volunteers [89]. Its effectiveness, however, in fondaparinux-related ICH has not yet been demonstrated [80]. Administration of rFVIIa (120 μg/kg) in healthy volunteers on dabigatran and rivaroxaban did not correct thrombin generation tests [81]. The long-term clinical impact of rFVIIa in patients with AICH remains to be tested in prospective studies.

Protamine

For symptomatic ICH with supratherapeutic aPTT associated with UFH, the infusion should be stopped and residual drug reversed using intravenous protamine sulfate at a ratio of 1 mg protamine per 100 units of UFH that was infused over the preceding 3 hours. Hemorrhagic conversion remains a threat up to 48 hours following reversal. Caution should be exercised by managing blood pressure [90], and the aPTT should be followed to monitor heparin neutralization. Side effects of protamine include hypotension, bradycardia, and anaphylactoid reactions. A paradoxical anticoagulant effect can be minimized by infusing protamine slowly, over 3 minutes, and avoiding doses greater than 50 mg at once. Protamine is less effective at neutralizing low molecular weight heparin (LMWH) because it only partially (60%) reverses its anti-factor Xa effect [80,91]. A longer half-life of subcutaneously administered LMWH further contributes to their sustained effects. Evidence-based guidelines on LMWH reversal is lacking. Following the manufacturer's recommendations, 1 mg protamine should be administered for every 1 mg enoxaparin (Sanofi-Aventis, Bridgewater, NJ, USA), and 1 mg protamine for every 100 anti-Xa IU dalteparin (Eisai Co. Ltd, Tokyo, Japan) or tinzaparin (LEO Pharmaceutical Products, Ballerup, Denmark) that was administered in the preceding 8 hours. If bleeding persists, an additional half-dose of protamine is recommended [80,91].

Antifibrinolytics

Tranexamic acid is an antifibrinolytic agent used for prevention of re-rupture of cerebral aneurysm after subarachnoid hemorrhage. Long-term use of tranexamic acid has been associated with hydrocephalus, thrombosis and delayed cerebral ischemia in this patient population [92]. Concomitant blood pressure reduction and rapid infusion of tranexamic acid has been shown to be associated with less frequent hematoma expansion in spontaneous ICH not
related to anticoagulant use [93]. Animal data on hemo-
static therapy with tranexamic acid in WRICH dem-
strated lower efficacy as compared with PCC and rFVIIa
and worsening perihematoma edema [94]. Since no anti-
dote is currently available for clinical use in dabigatran-
related major bleeding, some authorities recommend
administration of 1 g tranexamic acid [95]. In addition,
there is anecdotal experience of its use in a Jehovah’s Wit-
ness patient after post-tissue plasminogen activator-related
ICH to prevent hemorrhage expansion [96].

Special considerations with newer oral anticoagulants
To date, there are no specific antidotes available for clinical
use to reverse the anticoagulant effect of newer oral agents
such as dabigatran, apixaban, and rivaroxaban. Candidate
antidotes for dabigatran and factor Xa inhibitors have
demonstrated effectiveness in preclinical studies [97,98].
The proposed antidote for dabigatran is the antibody
aDabi-Fab that achieves an affinity for dabigatran 350 times
stronger than its affinity for thrombin. aDabi-Fab sup-
posedly has no prothrombotic effect [98]. The antidote for
factor Xa inhibitors could have wider applicability in revers-
ing both oral and parenteral agents, including LMWH and
fondaparinux. This antidote (PRT064445) reversed the
inhibition of factor Xa by direct factor Xa inhibitors and
corrected the prolongation of ex vivo clotting times in a
dose-dependent fashion. PRT064445 restored hemostasis
deranged by rivaroxaban in a rabbit model of liver
laceration [97]. In rats, the antidote dose-dependently and
completely corrected the increased blood loss caused by
enoxaparin and fondaparinux [97].

Until specific antidotes are available for clinical use, the
goal of treatment for AICH related to newer anticoagulants
is to restore coagulation by thrombin generation and to
overwhelm the effects of these agents with nonactivated
four-factor PCC, FEIBA™ or rFVIIa [99,100]. Other mea-
sures may include prevention of absorption by administer-
ing activated charcoal for recent ingestion and hemodialysis
or hemoperfusion [99]. The efficacy of prompt administra-
tion of activated charcoal has been demonstrated for dabi-
gatran with in vitro models [99] and for rivaroxaban and
apixaban with in vivo animal models [101,102]. In patients
taking dabigatran and undergoing hemodialysis, there was
an 85% reduction in plasma level at 60 minutes with
charcoal hemoperfusion [103,104]. Rivaroxaban is unlikely
to be dialyzable due to its high protein binding, although it
may theoretically be eliminated via plasma exchange. In
emergency situations such as AICH, however, neither
hemodialysis nor plasma exchange is practically feasible.

Other supportive measures
The general management of patients with AICH is outlined
in recent guidelines published by the American Heart
Association [105]. Here, we elaborate on the acute
management of hypertension and surgical interventions,
mostly relevant to intra-parenchymal bleed hemorrhages.

Anti-hypertensive therapy
In the acute phase of ICH, elevated blood pressure is
commonly encountered, with evidence linking acute hyper-
tension to increased mortality, disability, and possibly risk
of hematoma growth [106,107]. One argument against aggres-
sive treatment of acute hypertension in ICH, reducing
perfusion around the hematoma, was counteracted by
evidence from positron emission tomography studies
[108,109]. These studies and a handful of randomized con-
trolled trials, most notably the INTERACT-2 (Intensive
Blood Pressure Reduction in Acute Cerebral Hemorrhage
Trial – 2) study, showed that aggressive blood pressure low-
ering in ICH to treat systolic blood pressure ≤140 mmHg is
safe [110]. Although a difference in primary outcome was
absent, there was improved morbidity among patients
undergoing aggressive systolic blood pressure control.
Results of an ongoing similar trial, the ATACH-II (Anti-
hypertensive Treatment of Acute Cerebral Hemorrhage,
Phase III) trial, are awaited and could add to our knowledge
[111]. There remains a lack of consensus on how to manage
acutely elevated blood pressure in patients with AICH since
this population is excluded from acute ICH trials. However,
estimating results from spontaneous ICH trials seems
reasonable – although until such AICH trials are conducted,
clinicians should use clinical judgment and manage acute
hypertension on a case-by-case basis.

Surgery
The rationale to evacuate cerebral parenchymal hemor-
hages is to prevent thrombin and hemoglobin degradation-
product-mediated secondary brain damage. In addition,
surgical removal of blood clots alleviates pressure gradients
inside the skull and restores normal anatomy, thus
reducing or abolishing pressure on and injury to vital mid-
line diencephalic structures. There are no studies specifically
addressing the question of surgical evacuation of hematoma
in AICH, whether it is intra-parenchymal or elsewhere. In
clinical practice, and for obvious reasons, reversal of coagu-
lopathy precedes potential hematoma evacuation.

Randomized trials for spontaneous ICH go back to the
early 1960s. The STICH trial (International Surgical Trial
in Intracerebral Hemorrhage) randomized over 1,000
patients to early surgery (within 24 hours of randomization)
or initial conservative treatment, but failed to show any
clinical benefit of surgical evacuation [112]. Subgroup
analysis indicating potential benefit of surgery in superficial
ICH (<1 cm from cerebral surface) was the basis for the
recently concluded STICH II trial, in which primary
intention-to-treat analysis showed a small but nonsignifi-
cant increase in the number of patients having a favorable
outcome at 6 months in the early surgery group. There was
also a suggestion of a reduction in mortality, but this finding was also nonsignificant [113].

Surgical management after traumatic brain injury leading to acute epidural or subdural hemorrhage is generally indicated if the Glasgow Coma Scale score is ≤8 and there is a 5 mm or more shift on head computed tomography [114,115]. In a retrospective case series of 11 patients on oral phenprocoumon (vitamin K antagonist) presenting with acute subdural hemorrhage, the authors reported mortality of 45.5% at 6 months and the remaining patients were functionally independent during the same follow-up period [116]. Given the acuity and associated high morbidity and mortality of AICH, it is difficult to systematically study surgical therapy in this subgroup of patients.

**Resumption of anticoagulation**

Whether and when to resume anticoagulation are other important questions that haunt clinicians managing AICH. Again there is no straightforward and definitive answer to this dilemma. Very few data are available to guide clinicians on this important issue, and most of what we know is generated by small case series. The decision of whether to restart anticoagulation should take into consideration the recent anticoagulant-related hemorrhage and the need for anticoagulation. The evidence that supports use of anticoagulation in the disease process should be considered; and the urgency with which anticoagulation needs to be restarted and the risk of trauma/falls leading to rebleeding should also be a factor. The presence of microbleeds on brain magnetic resonance imaging might portend a higher risk of developing recurrent AICH once anticoagulation is restarted [117]. Finally, the availability of alternative approaches, in lieu of anticoagulation, to prevent progression of or complications from a thromboembolic disease process should be sought (for example, newer anticoagulants, temporary vena cava filter devices).

Claassen and colleagues reviewed medical records of 52 consecutive patients with WRICH [118]. Warfarin was restarted after a median of 10 days (range 7 to 28 days) in 23 patients; one-half of these had mechanical heart valves. During follow-up there were five cases of recurrent major bleeding in the group on warfarin, and five thromboembolic events in those not restarted on warfarin. In another retrospective study, Majeed and colleagues identified 234 patients with WRICH, 177 of whom had long-term follow-up [119]. Of these 177 patients, 59 resumed warfarin after a median of 5.6 weeks. Recurrent ICH occurred in eight patients who restarted warfarin and in 10 patients who did not. The combined risk of recurrent WRICH or ischemic stroke reached its nadir when warfarin was resumed 10 to 30 weeks after the incident WRICH.

In patients with a mechanical valve, the annual risk of systemic embolism is 4% per year, and the risk of valve thrombosis is 1.8% [59,64,120]. Given the risk of hematoma expansion and subsequent high morbidity associated with WRICH, it is advisable to withhold anticoagulation in the acute phase [59]. In the 2010 version of the American Heart Association guidelines, a specific mention of time to restart anticoagulation after WRICH was omitted [105]. The European stroke initiative suggests balancing the risk of recurrent ICH and thromboembolism in individuals with a strong indication for anticoagulation, and reinitiating the latter 10 to 14 days after the incident WRICH [64]. Practically, resumption of anticoagulation is debated among stroke experts and most agree to restart anticoagulation in 7 to 14 days provided benefits outweigh the risk and if the hemorrhage was deep in location [121].

**Conclusion**

Many questions pertaining to the management of AICH remain unanswered. Conducting a systematic randomized trial in this subpopulation of patients is difficult. The available literature (although mostly retrospective and case series) recommends rapid correction of coagulopathy, early surgical intervention if appropriate and holding resumption of anticoagulation during the acute phase. Newer oral anticoagulants are marketed to be safe with lower incidence of AICH and can be potentially considered when resumption of anticoagulation is warranted. However, the lack of optimal reversal agent in case of complications may deter clinicians from using them. The development of safe and novel reversal agents for newer generation anticoagulants should thus take precedence, given their booming use and the current naivety and inexperience of the healthcare provider in managing their hemorrhagic complications. Better studies are needed to guide clinicians in appropriate management and to help prognostication. Given the overall poor functional outcome of patients with ICH in general, and perhaps AICH in particular, a need exists to explore preventative avenues. Hence, emphasis should be also placed on patient education, lifestyle and risk modification and discussion of the risk–benefit ratio before anticoagulants are prescribed.

**Abbreviations**

AICH: Anticoagulant-related intracranial hemorrhage; aPTT: Activated partial thromboplastin time; FFP: Fresh frozen plasma; ICH: Intracerebral hemorrhage; INR: International Normalized Ratio; LMWH: Low molecular weight heparin; PCC: Prothrombin complex concentrate; PT: Prothrombin time; rFVIIa: Activated recombinant factor VII; UFH: Unfractionated heparin; WRICH: Warfarin-related intracerebral hemorrhage.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgements**

BR would like to acknowledge the research support received from the Neurocritical Care Division, Department of Neurological Surgery at UT Southwestern Medical Center, Dallas, TX, USA during his training.
37. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, Khatri P, Stettler B, Adeoye O, Moormann CJ, Broderick JP, Woo D: Warfarin use leads to a greater incidence of intracerebral hematomas. Neurology 2008, 71:1084–1089.

38. Flaherty ML: Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 2010, 30:565–572.

39. Cucchiara B, Nerse S, Sanning L, Kasner S, Lyden P: Hematoma growth in oral anticoagulant-related intracerebral hemorrhage. Stroke 2008, 39:2093–2096.

40. Dowlatshahi D, Butcher KS, Asadgh D, Nahim D, Bernbaum ML, Guli A, Wasserman JK, Poos MC, Coutts SB: Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012, 43:1812–1817.

41. Pengo V, Cippita L, Falanga A, Finazz G, Morongi F, Moia T, Pelleri G, Pol D, Testa S, Trafieri E, Tosetto A, Tendera S, Sanguassi S, Manetti C. Phase III study on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012, 10:1979–1987.

42. Levy JH, Dutton RP, Hembill JC, 3rd, Shander A, Cooper D, Paldus MA, Kessler CM, Holcomb JB, Lawson JH: Multidisciplinary approach to the challenge of hemostasis. Anesth Analg 2011, 113:534–364.

43. Crowther MA, Warkebin TE: Bleeding risk and the management of bleeding complications in patients undergoing anticoagulation therapy: focus on new anticoagulant agents. Blood 2008, 111:4871–4879.

44. Steiner T, Bohm M, Dichgans M, Diener HC, Cill C, Endres M, Dippel H, Peters J: Cohort study. 2010, 303.

45. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M: Progression of warfarin-associated intracerebral hemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006, 22:294–316.

46. van Ryn J, Stangier J, Hoet M, Liesenfeld KH, Wienen W, Feuring M, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C. Pharmacokinetics of Beriplix P/N prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013, 128:1234–1243.

47. Wolcik C, Schymk ML, Cure EG: Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009, 2:17–25.

48. Sorenson B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: Clinical review: Prothrombin complex concentrates – evaluation of safety and thrombogenicity. Crit Care 2011, 15:201.

49. Ray and Keyrouz

50. Chandler WL: Emergency assessment of hemostasis in the bleeding patient. Int J Emerg Med 2004, 57:1132–1139.

51. Schulman S: Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675–683.

52. Voorhees JE, Watson HG, Lowney KF, Eklund A, Wohn J, Laidlaw SL, Makris M, Preston FE: A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001, 115:145–149.

53. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:1605–1685.

54. Steiner T, Kaste M, Forsming M, Kweckels H, Zalka I, Juvula S, Marchal A, Chopet O, Cognard C, Unterberg A, Hacke W: Recommendations for the management of intracranial haemorrhage – part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006, 22:294–316.

55. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: Critical Care

56. Rosand J, Hylek EM, O’Donnell HC, Greenberg SW: Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology 2000, 55:947–951.

57. Appelboam A, Thomas EO: Warfarin and intracranial haemorrhage. Blood Rev 2009, 23:1–9.

58. Punthakee Z, Doobay J, Anand SS: Oral-anticoagulant-related intracerebral hemorrhage. Thromb Res 2002, 108:31–36.

59. Wijdicks EF, Schievink W, Brown RD, Mullaney C: The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurrgy 1998, 42:769–773.

60. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE: A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001, 115:145–149.

61. Ray and Keyrouz

62. Dominik M, Cerebral Haemorrhage. Chest 1989, 95:225–236.

63. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G: Pharmacology and management of the vitamin K antagonists: American College of Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:1605–1685.

64. Steiner T, Kaste M, Forsming M, Kweckels H, Zalka I, Juvula S, Marchal A, Chopet O, Cognard C, Unterberg A, Hacke W: Recommendations for the management of intracranial haemorrhage – part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis 2006, 22:294–316.

65. Holcomb JB: Rapid thrombelastography delivers real-time results that enhance clot susceptibility to fibrinolysis by mechanisms dependent on thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010, 8:790–798.

66. Selim MH, Molina CA: The role of hemostatic therapy in anticoagulation-associated intracerebral hemorrhage: intuition versus evidence. Stroke 2012, 43:2539–2540.
97. Lu G, Deguzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Claassen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA: Intracerebral hemorrhage. Neurology 2013, 80:163–168.

98. Senthil C, Schuster T, Forster MT, Seifert V, Gerlach R: The acute management of haemorrhage, surgery and traumatic brain injury. Neurosurgery 2013, 109:871–887.

99. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, Friedman J, Peters H, Clemens A: Effective elimination of dabigatran by haemodialysis. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2013, 109:217–224.

100. Devers RA, Kessler CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa. Ann Intern Med 2002, 137:884–888.

101. Johnson & Johnson Pharmaceutical Research & Development LLC: Advisory Committee Briefing Book: Rivaroxaban for the Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Patients Undergoing Hip or Knee Replacement Surgery. San Diego, CA: Johnson & Johnson Pharmaceutical Research & Development, LLC. 2009.

102. Elquis – Apixaban. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001246/human_med_001149.jsp&mid=W00102a00S00101D25.

103. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Hartter S, Friedman J, Peters H, Clemens A: Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haemostasis 2010, 40:5293.

104. Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr, Greenberg SM, Huang JN, MacDonald RI, Messe SR, Mitchell PH, Selim M, Tamargo RJ: Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 41:2108–2129.

105. Qureshi AI, Paisich Y, Martin R, Novitzke J, Cruz-Flores S, Ehtisham A, Ezzeddine MA, Goldstein JD, Hussein HM, Suri MF, Tan N: Effect of systolic blood pressure reduction on hematoma expansion, perihematoma edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 2010, 67:570–576.

106. Qureshi AI, Diringer MN: Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 2001, 57:18–28.

107. Zhang Y, Reilly KH, Tong W, Xu T, Chen J, Bazzano LA, Qiao D, Ju Z, Chen CS: The frequency of blood pressure and clinical outcome among patients with acute stroke in Inner Mongolia, China. J Hypertens 2008, 26:1464–1465.

108. Powers WJ, Zazulia AR, Videon TO, Adams RE, Yunndt KD, Aiyagari V, Grubb R Jr, Diringer MN: Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 2001, 57:18–28.

109. Zazulia AR, Diringer MN, Videon TO, Adams RE, Yunndt K, Aiyagari V, Grubb R Jr, Powers WJ: Hyperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 2001, 21:804–810.

110. Anderson CS, Heeley E, Hwang Y, Wang J, Staff C, Dekort C, Lindley R, Robinzon T, Lavados P, Neal B, Chen J, Anima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J, INTERACT2 Investigators: Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013, 368:2355–2365.

111. Qureshi AI, Paisich Y: Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH II): design, methods, and rationale. Neurocrit Care 2011, 15:559–576.

112. Mendekow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimnia A, Shaw MD, Barer DH: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387–397.

113. Mendekow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM, STICH II Investigators: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013, 382:397–408.

114. Bullock MR, Chernsrt R, Ghajar J, Gordon D, Hart R, Newell DW, Servadei F, Walters BC, Willerger JE: Surgical management of acute subdural hematomas. Neurosurgery 2006, 58:S16–S24: discussion Si-Siv.

115. Bullock MR, Chernsrt R, Ghajar J, Gordon D, Hart R, Newell DW, Servadei F, Walters BC, Willerger JE: Surgical management of acute epidural hematomas. Neurosurgery 2006, 58:S57–S55: discussion Si-Sv.

116. Senft C, Schuster T, Forster MT, Seifert V, Gerlach R: Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy. Neurol Res 2009, 31:102–108.

117. Lee SH, Ryu WS, Roh JK: Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology 2009, 72:171–176.

118. Claassen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA: Reversing warfarin-associated intracerebral hemorrhage. Neurocrit Care 2008, 9:1313–1318.
119. Majeed A, Kim YK, Roberts RS, Holmstrom M, Schulman S: Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010, 41:2860–2866.

120. Cannegieter SC, Rosendaal FR, Briet E: Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994, 89:635–641.

121. Steiner T: Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke 2011, 42:3661–3662.